PHIA Koninklijke Philips N.V.

Leading pathology laboratories deploy tele-diagnostics with Philips during the COVID-19 pandemic

Leading pathology laboratories deploy tele-diagnostics with Philips during the COVID-19 pandemic

November 18, 2020

  • Pathology laboratories around the globe fully digitize tumor tissue samples to maintain the patient diagnostic experience while providing for staff safety
  • Digital transformation modernizes cancer care by enabling telehealth and the use of artificial intelligence (AI) while supporting physicians with integrated oncology informatics

Amsterdam, The Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced leading pathology laboratories across North America, Europe, and Asia have implemented full digitization for their histology samples based on the Philips Digital Pathology scanner and imaging-informatics solutions. Digital images are required to unlock the potential of digital pathology. Remote reviewing of pathological cases is essential to prevent delay in critical patient diagnosis and care, particularly during COVID-19.

During the pandemic, many pathologists, oncologists, and radiologists continued their work from home. This created an unprecedented need for home workstations and secure clinical informatics solutions allowing clinicians to read images remotely and enabling real-time virtual collaboration between their multi-disciplinary care teams. Pre-COVID-19, pathology labs that digitized their workflows across different sites reported and an average .

Examples of leading pathology laboratories that recently transformed towards a digital workflow with Philips IntelliSite Pathology Solution are:  (Canada), Pathology Institute Tel Aviv Sourasky MC (Israel), (Netherlands), St. Olavs Hospital (Norway), (Singapore), (UK), and (UK).

“As healthcare becomes more complex and demanding, digitization has become a key enabler for the hospital to provide better care for our patients and to be more efficient. Digital pathology is an example, and our partnership with companies such as Philips with the clinical and technical know-how is important in helping us achieve our goal,” said Prof. Kenneth Kwek, Chief Executive Officer at Singapore General Hospital SGH.

“COVID-19 has become a catalyst for change – a defining moment for all of us to reimagine healthcare the way it should be,” said , Chief Business Leader, Precision Diagnosis at Philips. ”With a focus on the people at the center of cancer care, we work to innovate workflows, remove barriers of fragmented systems, and bring insights directly to care providers to support excellent cancer care.”

Shared decision-making, pathway selection and treatment

Philips’ solutions for oncology and digital pathology can help transform and enhance the multi-disciplinary workflows, including the oncology tumor board and care pathways process. Critical patient data is integrated for both oncologists, radiologists and pathologists, allowing them to collaborate efficiently, even when working remotely. The Philips platform supports streamlined preparation, enhances review and analysis, and empowers the cancer care team to reach clinical treatment decisions based on disease-specific dashboards, diagnostic images, reports, and structured patient data. Visit for more information on how Philips is enhancing digital pathology workflows. Visit to learn  how Philips integrated workflow solutions connect data, technology and people across the diagnostic enterprise, helping to redefine radiology workflow efficiencies.



For further information, please contact:

Kathy O’Reilly

Philips Global Press Office

Tel.:

E-mail :

Twitter:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .



Attachments



EN
18/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips unveils latest CT and MR innovations in radiation therapy, adv...

Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025 September 26, 2025 New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term valuePhilips debuts helium-free [2] BlueSeal RT 1.5T 70cm MR system with AI-powered SmartSpeed Precise, expanding its leadership in sustainable MR for radiation oncology Amsterdam, the Netherlands – At the American Society for Radiation Oncology () 2025 Annual Meeting, (NYSE: PHG, AEX: PHIA), a global leader in health technolog...

 PRESS RELEASE

Philips joins Optum Healthcare’s network as a preferred provider in th...

Philips joins Optum Healthcare’s network as a preferred provider in the USA September 25, 2025 Philips’ ambulatory and diagnostic solutions and services are now available to 3.4 million Optum policyholders for enhanced outpatient cardiac monitoring Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has entered a national partnership in the USA with Optum Healthcare. The inclusion of Philips’ (MCOT) and Philips Extended Holter (ePatch) in the network is designed to enable earlier detection of cardiac conditions and timely cli...

 PRESS RELEASE

Philips intends to extend maturity of forward purchases of 4 million s...

Philips intends to extend maturity of forward purchases of 4 million shares for long-term incentive plans September 15, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA) announces today that it intends to extend the settlement of two forward contracts for 2 million long-term incentive plans shares each as part of the share repurchase program on June 14, 2023. The planned extension will postpone the original maturity dates in Q4 2025 by one year to a new maturity date in Q4 2026. Further details will be available via this . For further information, please contact:Michael FuchsPhil...

 PRESS RELEASE

Philips and Masimo announce innovation partnership to advance access t...

Philips and Masimo announce innovation partnership to advance access to patient monitoring measurement technologies September 11, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and (NASDAQ: MASI) today announced that the two companies have renewed their multi-year strategic collaboration, marking a fresh chapter in their long-standing partnership. With a shared commitment to innovation and expanding access to high-quality, connected care, the two companies are taking a bold new approach in accelerating the development and delivery of next-...

 PRESS RELEASE

Philips launches smart telemetry platform for cardiac monitoring that ...

Philips launches smart telemetry platform for cardiac monitoring that provides continuous, enterprise-wide connectivity beyond the bedside September 4, 2025 Empowering clinical teams to respond to surges, track usage and ease workflows with user-friendly touchscreen technology for telemetry patients on the move Cambridge, Massachusetts – , a global leader in health technology, today announced the introduction of an  designed to help address critical challenges in healthcare – including staff shortages and alarm management. A key component of the solution is the next-generation Telemetry M...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch